Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 20;20(23):5819.
doi: 10.3390/ijms20235819.

Targeting Tumor Endothelial Cells with Nanoparticles

Yu Sakurai  1 , Hidetaka Akita  1 , Hideyoshi Harashima  2
Affiliations
Review

Targeting Tumor Endothelial Cells with Nanoparticles

Yu Sakurai et al. Int J Mol Sci. .

Abstract

Because angiogenesis is a major contributor to cancer progression and metastasis, it is an attractive target for cancer therapy. Although a diverse number of small compounds for anti-angiogenic therapy have been developed, severe adverse effects commonly occur, since small compounds can affect not only tumor endothelial cells (TECs), but also normal endothelial cells. This low selectivity for TECs has motivated researchers to develop alternate types of drug delivery systems (DDSs). In this review, we summarize the current state of knowledge concerning the delivery of nano DDSs to TECs. Their payloads range from small compounds to nucleic acids. Perspectives regarding new therapeutic targets are also mentioned.

Keywords: anti-angiogenic therapy; drug delivery system; nanoparticles; nucleic acids; tumor endothelial cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971;285:1182–1186. - PubMed
    1. Gospodarowicz D., Brown K.D., Birdwell C.R., Zetter B.R. Control of proliferation of human vascular endothelial cells. Characterization of the response of human umbilical vein endothelial cells to fibroblast growth factor, epidermal growth factor, and thrombin. J. Cell Biol. 1978;77:774–788. doi: 10.1083/jcb.77.3.774. - DOI - PMC - PubMed
    1. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D.T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312. doi: 10.1126/science.2479987. - DOI - PubMed
    1. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309. doi: 10.1126/science.2479986. - DOI - PubMed
    1. Frandsen S., Kopp S., Wehland M., Pietsch J., Infanger M., Grimm D. Latest results for anti-angiogenic drugs in cancer treatment. Curr. Pharm. Des. 2016;22:5927–5942. doi: 10.2174/1381612822666160715130419. - DOI - PubMed

MeSH terms

LinkOut - more resources